LRP5 and osteoporosis: Sclerostin, an osteocyte-specific glycoprotein that inhibits the canonical Wnt pathway (similarly to DKK1 by binding to LRP5/6 [57]) is the target of romosozumab, the humanized monoclonal antibody treatment for osteoporosis [58].